Stay updated on Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T23:14:49.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the complete response rate expected in patients with Relapsed Refractory Hodgkin Lymphoma and non-Hodgkin lymphoma when treated with the combination of Pembrolizumab and Lenalidomide.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:54.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for participants who meet specific health conditions or prior treatments. This change provides more context and examples of what eligibility criteria entail.
    Difference
    52%
    Check dated 2024-05-22T21:37:33.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:42:45.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page.